Little response to zoledronic acid in a child of juvenile myelomonocytic leukemia (JMML) harboring the PTPN11 mutation.
Shimada
H
H
Shima
H
H
Shimasaki
N
N
Yoshihara
H
H
Mori
T
T
Takahashi
T
T
D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D002675:Child, Preschool; D004164:Diphosphonates / Q000627:therapeutic use*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D047908:Intracellular Signaling Peptides and Proteins / Q000235:genetics*; D015479:Leukemia, Myelomonocytic, Acute / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics; D008297:Male; D009154:Mutation; D054592:Protein Tyrosine Phosphatase, Non-Receptor Type 11; D017027:Protein Tyrosine Phosphatases / Q000235:genetics*; D054593:SH2 Domain-Containing Protein Tyrosine Phosphatases; D016896:Treatment Outcome; D000077211:Zoledronic Acid; D018909:src Homology Domains
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D047908:Intracellular Signaling Peptides and Proteins; D000077211:Zoledronic Acid; C516724:PTPN11 protein, human; D054592:Protein Tyrosine Phosphatase, Non-Receptor Type 11; D017027:Protein Tyrosine Phosphatases; D054593:SH2 Domain-Containing Protein Tyrosine Phosphatases